Purdue Finds New IDH‑Mutant Protein Modification
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- W. Andy Tao led the Purdue research that uncovered a chiral-dependent protein modification driven by D‑2‑hydroxyglutarate (D2HG) and L‑2‑hydroxyglutarate (L2HG) in IDH1‑mutant cells, as reported in Nature Chemistry.
- IDH1 mutation appears in over 70% of certain cancers such as glioma, acute myeloid leukemia, and rare liver cancer, and triggers accumulation of D2HG, which modifies dozens of proteins linked to tumor progression.
- Nature Chemistry published the study (2026) detailing the identification of dozens of D2HG‑modified proteins and highlighting their potential regulatory role in cancer development.
- PolyMAC, a polymer‑based metal ion affinity capture method introduced by Tao’s lab in 2010, was employed to enrich and detect the modified proteins.
- Phosphorylation pathways crosstalk with D2HG/L2HG modifications was observed, indicating that the new modification may intersect with known signaling pathways in cancer cells.
- Tymora Analytical Operations, co‑founded by Tao, commercialized the PolyMAC enrichment kit used in the study.
Why it matters: The finding gives drug developers a new molecular target in IDH1‑mutant tumors, potentially expanding treatment options for glioma, AML and certain liver cancers, while also prompting researchers to consider chiral metabolite modifications alongside phosphorylation in cancer biology, accelerating therapeutic innovation.
Ask SkimNews
